Merit Medical Systems (NASDAQ:MMSI) Price Target Raised to $109.00 at Barrington Research

Merit Medical Systems (NASDAQ:MMSI) had its price objective raised by Barrington Research from $106.00 to $109.00 in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has an outperform rating on the medical instruments supplier’s stock.

Several other brokerages have also recently weighed in on MMSI. Wells Fargo & Company reduced their price objective on Merit Medical Systems from $103.00 to $95.00 and set an “overweight” rating on the stock in a research note on Friday, November 14th. Piper Sandler cut their target price on Merit Medical Systems from $113.00 to $106.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 18th. Needham & Company LLC decreased their price target on Merit Medical Systems from $108.00 to $101.00 and set a “buy” rating on the stock in a report on Wednesday. Robert W. Baird set a $108.00 price objective on shares of Merit Medical Systems in a research note on Tuesday, December 16th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Merit Medical Systems in a research report on Monday, December 29th. Nine analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merit Medical Systems currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.22.

Merit Medical Systems Trading Down 3.9%

MMSI stock opened at $79.23 on Wednesday. The firm has a fifty day moving average price of $83.92 and a 200 day moving average price of $84.94. Merit Medical Systems has a fifty-two week low of $77.62 and a fifty-two week high of $107.27. The firm has a market cap of $4.70 billion, a PE ratio of 37.37, a price-to-earnings-growth ratio of 2.24 and a beta of 0.61. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.86 and a current ratio of 4.28.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings data on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, beating the consensus estimate of $0.96 by $0.08. Merit Medical Systems had a net margin of 8.48% and a return on equity of 14.06%. The business had revenue of $393.94 million during the quarter, compared to analyst estimates of $390.77 million. During the same quarter last year, the business earned $0.93 earnings per share. Merit Medical Systems’s quarterly revenue was up 10.9% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Sell-side analysts anticipate that Merit Medical Systems will post 3.37 earnings per share for the current fiscal year.

Institutional Trading of Merit Medical Systems

Institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC boosted its stake in shares of Merit Medical Systems by 7.3% during the first quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier’s stock valued at $1,730,000 after purchasing an additional 1,114 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Merit Medical Systems by 16.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier’s stock valued at $76,039,000 after buying an additional 103,878 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its position in Merit Medical Systems by 6.0% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 19,803 shares of the medical instruments supplier’s stock valued at $1,851,000 after buying an additional 1,114 shares during the period. Envestnet Asset Management Inc. grew its stake in Merit Medical Systems by 5.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 244,163 shares of the medical instruments supplier’s stock worth $22,824,000 after acquiring an additional 12,256 shares in the last quarter. Finally, Whalen Wealth Management Inc. increased its position in shares of Merit Medical Systems by 22.0% during the second quarter. Whalen Wealth Management Inc. now owns 4,755 shares of the medical instruments supplier’s stock worth $445,000 after acquiring an additional 856 shares during the period. 99.66% of the stock is currently owned by institutional investors.

Key Headlines Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q4 beat — Merit reported $1.04 EPS vs. $0.96 consensus and revenue of $393.9M (vs. $390.8M), with margins expanding and Cardiovascular, U.S. and EMEA sales strong. This fundamental beat supports upside. Article Title
• Positive Sentiment: Raised FY‑2026 guidance — company set EPS guidance of $4.01–$4.15 vs. street ~$3.73, signaling stronger forward earnings potential that underpins valuation. Article Title
• Positive Sentiment: Analyst upgrade — Barrington Research raised its price target to $109 and gave an “outperform” rating, signaling consensus upside from current levels. Article Title
• Neutral Sentiment: Strategic update — Merit projects 6%–8% revenue growth for 2026 while divesting its DualCap business to sharpen focus on global platform strength; this is strategically constructive but will take time to flow to results. Article Title
• Neutral Sentiment: Analyst commentary notes — coverage writeups (TipRanks/Yahoo summaries) emphasize the strong quarter and upbeat outlook even where price targets were adjusted, suggesting analysts remain broadly constructive. Article Title
• Negative Sentiment: Price‑target chop adds volatility — Needham trimmed its PT to $101 from $108 (kept Buy), and mixed analyst PT moves introduce near‑term selling pressure and uncertainty despite fundamentals. Article Title

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.